Iterum Therapeutics (ITRM) intends to raise $80 million in an IPO from the sale of common stock, per an amended registration statement.
The company is developing a pipeline of treatment candidates for urinary tract and intra-abdominal infections.
ITRM is preparing to enter Phase 3 trials for its in-licensed drugs from Pfizer. If those trials go well, I wouldn't be surprised if Pfizer acquires Iterum.
Check, a first-of-its-kind payroll infrastructure startup whose mission is to make paying people simple, announced its public launch today with $35 million in Series B funding from Stripe and Thrive Capital.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated New York attorney Karina E. Murski
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
